Make ABN Newswire your homepage | Add to Favourites
 CHINESE SIMPLE   CHINESE TRAD     JAPANESE     KOREAN
 ENGLISH    ARABIC    EUROPE
 
  Home    |   Media Partners    |    About Us   |   Contact Us
 
Home News
 

Melbourne, Jan 17, 2008 (ABN Newswire) - The Directors are pleased to announce that Solagran Limited (ASX: SLA) has engaged the Bank of New York to establish a level one American Depository Receipt (ADR) Program.

This ADR Program will make Solagran securities more accessible to the US institutional and retail investors, without incurring the compliance costs of a full exchange listing. It will help facilitate the purchase of Solagran securities by US Investors.

The Directors believe the ADR Program is an important step towards the eventual establishment of a production facility in North America and licensing agreements for product distribution in the region.


About SOLAGRAN LIMITED

Solagran is a biotechnology company with a portfolio of higly effective, low side effect, natural pharmaceuticals that it obtains from gree tree foliage. Its patented technology enables the extraction of the live elements of trees in a way that both preserves and amplifies their biological activity.


  Related Companies

>>>    SOLAGRAN LIMITED

 

 
 
Solagran Limited (ASX:SLA) Announce ADR (American Depository Receipt) Program
 
SOLAGRAN LIMITED
2008.04.22  12:48
Solagran Limited (ASX:SLA) Update on Ropren Production and Marketing In Russia

2008.04.02  09:46
Solagran (ASX:SLA) Announce Marketing Strategy Details For Ropren In Russia

2008.03.27  12:46
Solagran Opens Commercial Scale Plant for Pharmaceutical Grade Polyprenols

2008.03.27  12:40
Solagran Limited (ASX:SLA) Announce Formal Opening Of Russian Facility

2008.03.19  11:37
Solagran Limited (ASX:SLA) Announce Approval Of ROPREN for Sale In Russia

 
Asia Business News
Submit Press
News Alerts by Email
Home | Contact Us | About Us
Copyright 2008 Asia Business News Ltd.